Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SUR1-Kir6.2 complex is a hetero-octameric ATP-sensitive potassium (KATP) channel that serves as a critical metabolic sensor in pancreatic beta cells and specific neuronal populations [1, 2, 4]. It is composed of four pore-forming inwardly rectifying potassium channel 6.2 (Kir6.2) subunits and four regulatory sulfonylurea receptor 1 (SUR1) subunits [2, 11, 14]. By sensing the intracellular ATP-to-ADP ratio, the channel couples cellular metabolism to membrane excitability; an increase in ATP leads to channel closure, membrane depolarization, and the subsequent release of insulin [1, 8, 11]. Dysregulation of this complex due to genetic mutations results in severe metabolic disorders, including neonatal diabetes (gain-of-function) and congenital hyperinsulinism (loss-of-function) [1, 4, 6, 11]. This channel is a major therapeutic target, with sulfonylurea drugs acting as blockers to stimulate insulin secretion in type 2 diabetes, while openers like diazoxide are used to suppress insulin overproduction in hypoglycemic conditions [12, 15].
Sulfonylureas and glinides act as channel blockers by binding to the SUR1 subunit, leading to channel closure, membrane depolarization, and stimulated insulin release [1, 8, 11, 12]. Conversely, potassium channel openers like diazoxide bind to SUR1 to maintain the channel in an open state, causing hyperpolarization and inhibition of insulin secretion [12, 15].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP-sensitive potassium channel (Sulfonylurea receptor 1-Inwardly rectifying potassium channel 6.2) (KATP channel).